Breaking news on epilepsy
Scientists Decode Words From Brain Signals published
Tue, 07 Sep 2010 01:00:00 PDT
In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain...
Depression Significantly Improved By Non-Invasive Therapy published
Mon, 06 Sep 2010 00:00:00 PDT
Major depression is a common and disabling brain condition marked not only by the presence of depressed mood but also by its effects on sleep, energy, decision-making, memory and thoughts of death or of suicide. Major depression affects 15 million adults in the U.S...
U.S. Neurologists Agree On Protocols For Treatment Of Infantile Spasms published
Sat, 04 Sep 2010 01:00:00 PDT
Researchers from across the U.S., as part of the Infantile Spasms Working Group (ISWG), established guidelines for the diagnosis and treatment of infantile spasms (IS). The goal of the ISWG is to improve patient outcomes by creating protocols that educate pediatricians on early diagnosis and treatment options...
Position Statements About The Post-Reproductive Health Of Women Published By EMAS published
Sat, 04 Sep 2010 00:00:00 PDT
Elsevier has announced the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas on common management problems in the post-reproductive health of women. The statements cover the management of the menopause in the context of obesity, epilepsy, endometriosis and premature ovarian failure...
GSK And Valeant Announce New U.S. FDA PDUFA Goal Date For Ezogabine published
Wed, 01 Sep 2010 02:00:00 PDT
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010. The original goal date was 30 August 2010...
Study Shows Brain Trauma Associated With Lifelong Conditions That Affect Quality Of Life And Mortality published
Mon, 30 Aug 2010 01:00:00 PDT
Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston...
High-Fat Diets Effectively Treat Absence Epilepsy published
Fri, 27 Aug 2010 00:00:00 PDT
Two high-fat diets the classic ketogenic and a modified version of the Atkins can reduce and, in some cases, completely eliminate seizures in children with a common seizure disorder known as absence epilepsy, say researchers from Johns Hopkins Children's Center...
Gene Therapy To Treat Epilepsy A Step Closer published
Thu, 26 Aug 2010 02:00:00 PDT
Current antiepileptic drugs (AEDs) have many side-effects, among others slowing down brain activity, which in turn reduces patients' ability to react. These side-effects could be eliminated if genes that counteract seizures could be introduced into the brain. Professor Merab Kokaia at Lund University in Sweden has obtained promising results in animal experiments...
Eisai Announces Positive Phase III Trial Results For Perampanel In Epilepsy published
Thu, 26 Aug 2010 01:00:00 PDT
Eisai Inc. announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered by Eisai and being developed for treatment of partial seizures in patients with epilepsy...
Cyberonics Announces Epilepsy Technology Agreements published
Wed, 25 Aug 2010 04:00:00 PDT
Cyberonics, Inc. (Nasdaq: CYBX) announced that it has entered into additional agreements with NeuroVista Corporation in the field of EEG-based seizure detection to build on its position as the leader in medical devices for epilepsy...
Eisai Announces Positive Results Of Phase III Trial For Perampanel In Epilepsy published
Wed, 25 Aug 2010 04:00:00 PDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced that results of a Phase III study in epilepsy patients with refractory partial seizures demonstrate the clinical benefits of the novel investigational compound E2007 (generic name: perampanel)...
Epilepsy Organizations Award Grants For New Gene Therapy To Treat Epilepsy And Novel Surgical Intracranial EEG published
Tue, 24 Aug 2010 02:00:00 PDT
The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) announced the latest grant recipients of its New Therapy Grants Program, a unique joint venture of the non-profit epilepsy organizations, to advance promising epilepsy research in clinical development...
Ezogabine, An Investigational Anti-Epileptic Drug, Receives Positive Vote From FDA Advisory Committee published
Thu, 12 Aug 2010 02:00:00 PDT
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced that a U.S. Food and Drug Administration (FDA) advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures...
New Epilepsy Research Will Help To Reduce Animal Experiments published
Tue, 10 Aug 2010 01:00:00 PDT
A new epilepsy research project led by the University of Bath is developing a new technique to reduce the number of animals used for each experiment by 90 per cent and give more accurate results. Epilepsy affects around 50 million people worldwide; nearly 1000 people a year in the UK die directly or indirectly from the condition, which causes recurrent seizures...
Solving The Mystery Of Bone Loss From Drug For Epilepsy And Bipolar Disorder published
Wed, 04 Aug 2010 11:00:00 PDT
Scientists are reporting a possible explanation for the bone loss that may occur following long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. The drug, valproate, appears to reduce the formation of two key proteins important for bone strength, they said...
Possible Link Between Epileptic Seizures And An Ancient Gene Family published
Mon, 02 Aug 2010 02:00:00 PDT
New research points to a genetic route to understanding and treating epilepsy. Timothy Jegla, an assistant professor of biology at Penn State University, has identified an ancient gene family that plays a role in regulating the excitability of nerves within the brain. "In healthy people, nerves do not fire excessively in response to small stimuli...
Research Study Opens The Door To New Class Of Drugs For Epileptic Seizures published
Fri, 30 Jul 2010 00:00:00 PDT
A chemical compound that boosts the action of a molecule normally produced in the brain may provide the starting point for a new line of therapies for the treatment of epileptic seizures, according to a new study by scientists at The Scripps Research Institute...
Certain Epilepsy Drugs May Increase Risk Of Suicide published
Wed, 28 Jul 2010 02:00:00 PDT
While the Food and Drug Administration (FDA) requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk. The study is published in the July 27, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology...
Women Help Women Live And Cope With Epilepsy In The Family published
Thu, 22 Jul 2010 01:00:00 PDT
A new campaign explores the roles and responsibilities women uniquely encounter when living, or caring for a loved one, with epilepsy. "Women Succeeding with Epilepsy" is a collaboration between Epilepsy Advocate and HealthyWomen to educate, empower and inspire women and families whose lives are affected by epilepsy...
FDA Accepts Historical Controls For Epilepsy Monotherapy Studies published
Wed, 21 Jul 2010 02:00:00 PDT
New York University researchers revealed that data from previously completed withdrawal to monotherapy studies for antiepileptic drugs (AEDs) provide a valid control for future studies, obviating the need for placebo/pseudo-placebo trials to demonstrate the efficacy of these drugs as monotherapy...
FDA Accepts BANZEL(R) (Rufinamide) Oral Suspension NDA For Review published
Wed, 21 Jul 2010 00:00:00 PDT
Eisai Inc. (Headquarters: Woodcliff Lake, NJ; President and CEO: Lonnel Coats), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) announced that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's NDA for BANZEL® (rufinamide) Oral Suspension (40 mg/mL)...
Soldiers With Brain Injuries At Higher Risk Of Epilepsy Decades Later published
Tue, 20 Jul 2010 03:00:00 PDT
Soldiers who receive traumatic brain injuries during war may be at a higher risk of epilepsy even decades after the brain injury occurred. The new research is published in the July 20, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology...
Research Project Analyses Cerebral Bioelectricity In Order To Detect Epilepsy published
Tue, 20 Jul 2010 01:00:00 PDT
A group of researchers from Universidad Carlos III de Madrid (UC3M) has presented a new algorithm that uses a new method to analyse the information obtained from electroencephalograms to detect neurodegenerative diseases, such as epilepsy, using the bioelectric signals of the brain...
NeuroPace Submits PMA Application For FDA Approval Of Novel Investigational Device For Epilepsy published
Fri, 09 Jul 2010 02:00:00 PDT
NeuroPace, Inc. announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur...
Epilepsy Nurses Encouraged To Take The Right Path, UK published
Thu, 08 Jul 2010 01:00:00 PDT
A new learning and development pathway programme has been produced for Nurses working at the National Centre for Young People with Epilepsy (NCYPE). The national epilepsy charity has a world class medical centre - the Neville Childhood Epilepsy Centre - as part of its 60 acre campus in Lingfield, Surrey...
)
|
|
